5:18 PM
 | 
Mar 12, 2012
 |  BC Extra  |  Clinical News

Tranzyme falls after ulimorelin misses Phase III endpoint

Tranzyme Inc. (NASDAQ:TZYM) fell $2.20 (43%) to $2.90 on Monday after ulimorelin missed the primary endpoint of time to recovery of GI function vs. placebo in the Phase III ULISES 007 trial to...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >